UNSPSC 51281817: Doxorubicin aglycone

This classification denotes a doxorubicin preparation with the molecular formula C21H18O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X023T6C35L, chemically known as 5,12-naphthacenedione, 7,8,9,10-tetrahydro-6,8,10,11-tetrahydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8s,10s)-, but more generally known as doxorubicin aglycone, which bears US NIH Compound Identifier 72401. European Medicines Agency schedules doxorubicin aglycone or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06391MIG.

Most nations, for tariff purposes, schedule doxorubicin aglycone under HS 29419000. SMILES: COC1CCCC2C1C(=O)C3C(C(C4C(C3O)[C@H](C[C@@](C4)(C(=O)CO)O)O)O)C2=O.

UNSPSC 51281817 Doxorubicin aglycone is a Commodity code that nominally identifies a specific chemotherapy agent, but recent state and local contract opportunities tagged under this code show minimal direct relevance to the code's pharmaceutical scope. The recent solicitations posted under this code span medical and first aid supplies procurement (including respiratory equipment, cardiac monitoring electrodes, and emergency consumables), naloxone and drug deactivation systems for community health, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and exploratory procurement for direct-to-manufacturer pharmacy benefit initiatives. The issuing bodies include county health departments, city fire departments, state health and human services agencies, and cooperative purchasing alliances serving multiple state and local jurisdictions. The mismatch between the code's nominal identity as a single chemotherapy compound and the breadth of pharmaceutical and medical supply purchases tagged to it suggests either miscoding at source or use of the code as a catch-all for pharmaceutical procurement.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa Fire Department issued an IFB (26P00145) on March 25, 2026, for medical and first aid supplies with an estimated contract value of $700,000 and a due date of March 13, 2026, designated as sheltered for certified Small Local Business Enterprises with a 5 percent bid discount not to exceed $10,000. Seminole County, Florida solicited naloxone and drug deactivation systems (IFB 60459723LAS, due July 26, 2023) for quarterly delivery of 1,900 units of naloxone and 800 deactivation systems annually. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with performance weighted 75 percent on price competitiveness and contracts effective July 1, 2026. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013, posted April 3, 2026) to explore vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, indicating early-stage procurement development with no formal award timeline or budget identified.